Scientists have developed an artificial intelligence-powered model that may help identify premature infants at risk for pulmonary hypertension (PH) and bronchopulmonary dysplasia (BPD) using noninvasive eye pictures taken during standard screenings. “Our findings suggest that information about a baby’s lung and heart health may already be present in these…
Following positive results from a Phase 3 clinical study, United Therapeutics plans to submit an application to the U.S. Food and Drug Administration (FDA) by the second half of 2026 seeking approval for its experimental oral therapy ralinepag as a treatment for pulmonary arterial hypertension (PAH). United announced…
GSK (formerly called GlaxoSmithKline) has acquired rights to HS235, an experimental treatment for pulmonary hypertension (PH), now in early clinical testing, that the buyer hopes will become a new standard of care for PH. The therapy’s developer 35Pharma announced that it’s being acquired by GSK for $950…
Discussion
Note: This column describes the author’s own experiences with intravenous therapy. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. When I was diagnosed with pulmonary hypertension (PH), my doctors recommended intravenous (IV) therapy rather than oral medications. They explained…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
